Renoprotective Effects of DPP-4 Inhibitors

Kawanami, Daiji; Yuasa, Takashi; Takahashi, Hiroyuki; Motonaga, Ryoko; Tanabe, Makito

doi:10.3390/antiox10020246

Cited by 19 publications

(26 citation statements)

References 134 publications

(180 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SGLT2 inhibitors as in the present study, thiazolidinediones [ 24 ], DPP4 inhibitors [ 25 ], and GLP-1 agonists [ 26 ] reportedly attenuate albuminuria in obese or diabetic model mice. We proposed that the SGLT2 inhibitor-specific mechanism by which Ipra suppresses DN development in HFD-fed mice involves decreased leptin production from PRAT by Ipra.…”

Section: Discussionmentioning

confidence: 59%

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice

Okuma

Mori

Nakamura

et al. 2021

IJMS

View full text Add to dashboard Cite

Sodium glucose cotransporter-2 (SGLT2) inhibitors inhibit the development of diabetic nephropathy (DN). We determined whether changes in perirenal fat (PRAT) by a SGLT2 inhibitor ipragliflozin (Ipra) contribute to the suppression of DN development. High-fat diet (HFD)-fed mice were used as a DN model and were treated with or without Ipra for 6 weeks. Ipra treatment reduced urinary albumin excretion (UAE) and glomerular hypertrophy in HFD-fed mice. In the PRAT of Ipra-treated mice, adipocyte size was increased, and inflammation, fibrosis, and adipocyte death were suppressed. In conditioned medium made from PRAT (PRAT-CM) of Ipra-treated mice, the concentration of leptin was significantly lower than PRAT-CM of mice without Ipra treatment. Serum leptin concentration in renal vein positively correlated with UAE. PRAT-CM from HFD-fed mice showed greater cell proliferation signaling in mouse glomerular endothelial cells (GECs) than PRAT-CM from standard diet-fed mice via p38MAPK and leptin-dependent pathways, whose effects were significantly attenuated in PRAT-CM from Ipra-treated mice. These findings suggest that Ipra-induced PRAT expansion may play an important role in the improvement of DN in HFD-fed mice. In vitro experiments suggest that reduced PRAT-derived leptin by Ipra could inhibit GECs proliferation, possibly contributing to the suppression of DN development.

show abstract

Section: Discussionmentioning

confidence: 59%

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice

Okuma

Mori

Nakamura

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Collection (1) In-line Preservation (2) Nil Transport (3) Nil Storage (4) Nil Type of method: direct or indirect ( 5) Direct (no sample preparation) Scale of extraction (6) Nil Solvents/reagents used (7) Green Solvents Additional treatments (8) Nil Reagent and solvents Amount (9) <10 mL Health hazard (10) Ethanol, slightly toxic and irritant NFPA score 1…”

Section: Category Uv Spectrophotometric Methods Sample Preparationmentioning

confidence: 99%

“…Nil Type of method: direct or indirect (5) Direct (no sample preparation) Scale of extraction (6) Nil Solvents/reagents used (7) Green Solvents Additional treatments (8) Nil…”

Section: Category Uv Spectrophotometric Methods Sample Preparationmentioning

confidence: 99%

Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation

et al. 2021

View full text Add to dashboard Cite

Three rapid, accurate, and ecofriendly processed spectrophotometric methods were validated for the concurrent quantification of remogliflozin (RGE) and vildagliptin (VGN) from formulations using water as dilution solvent. The three methods developed were based on the calculation of the peak height of the first derivative absorption spectra at zero-crossing points, the peak amplitude difference at selected wavelengths of the peak and valley of the ratio spectra, and the peak height of the ratio first derivative spectra. All three methods were validated adapting the ICH regulations. Both the analytes showed a worthy linearity in the concentration of 1 to 60 µg/mL and 2 to 90 µg/mL for VGN and RGE, respectively, with an exceptional regression coefficient (r2 ≥ 0.999). The developed methods demonstrated an excellent recovery (98.00% to 102%), a lower percent relative standard deviation, and a relative error (less than ± 2%), confirming the specificity, precision, and accuracy of the proposed methods. In addition, validated spectrophotometric methods were commendably employed for the simultaneous determination of VGN and RGE from solutions prepared in the laboratory and the formulation. Hence, these methods can be utilized for the routine quality control study of the pharmaceutical preparations of VGN and RGE in pharmaceutical industries and laboratories. The ecofriendly nature of the anticipated spectrophotometric procedures was confirmed by the evaluation of the greenness profile by a semi-quantitative method and the quantitative and qualitative green analytical procedure index (GAPI) method.

show abstract

“…Notably, the DPP-4 enzyme is observed in various renal membrane-bound locations, such as vascular smooth muscle cells in the afferent arteriolar, mesangial cells, podocytes, and proximal tubular cells [11,12]. DPP-4 (aka as CD26) is expressed as a type II transmembrane glycoprotein, with a short 6-amino acid cytoplasmic tail.…”

Section: The Potential Renal Protection Site Of Dpp-4 Inhibitors In Type-2 Diabetes Mellitusmentioning

confidence: 99%

“…DPP-4 (aka as CD26) is expressed as a type II transmembrane glycoprotein, with a short 6-amino acid cytoplasmic tail. Its monomer weight molecular weight is 110 kDa however it usually shows its activity as a dimer [12]. Besides, DPP-4 inhibitors appear to have beneficial albuminuria effects, similar to those with GLP-1 agents [11].…”

Section: The Potential Renal Protection Site Of Dpp-4 Inhibitors In Type-2 Diabetes Mellitusmentioning

confidence: 99%

The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease

Alqurashi¹,

Alharthi²,

Alshehri³

et al. 2021

Pharmacophore

View full text Add to dashboard Cite

The most popular type of diabetes is Type-2 diabetes mellitus (T2DM) accounting for 90-95% of diagnosed diabetes and continues to overgrow worldwide and in the USA. This rapid growth may be attributed to the increased elderly population, prevalence of obesity among adults and children, socioeconomic development, urbanization, unhealthy diets, and poor physical activities. The administration of antidiabetic agents in addition to cardio-renal protection is strongly required. Adequate glycemic control must be achieved with protection against cardiovascular and renal outcomes simultaneously. DPP-4 inhibitors are novel antidiabetic agents that have recently demonstrated protection against macro and macrovascular diabetes complications, particularly cardio-renal protection. To evaluate the efficacy and safety of DPP-4 inhibitors on chronic kidney disease patients. We used the PubMed database and searched for relevant articles on the topic. We used the Mesh word searching system; DPP-4 inhibitors; complications; adverse reactions. Type-2 Diabetes mellitus; Chronic kidney disease. DPP-4 inhibitors have demonstrated promising renal protection in healthy animal studies. Nevertheless, in humans with type-2 diabetes mellitus, the renal impact is still controversial. Several randomized clinical trials support the renoprotection effect of diabetic nephropathy.

show abstract

Renoprotective Effects of DPP-4 Inhibitors

Cited by 19 publications

References 134 publications

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice

Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation

The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease

Contact Info

Product

Resources

About